Cequa™ (formerly Seciera™) - Dry Eye Syndrome

Auven Therapeutics completed discovery and development of Cequa™ (cyclosporine ophthalmic solution) for the treatment of Dry Eye disease and has sold Cequa™ to Sun Pharmaceuticals after completion by Auven of the last 2 phase 3 trials. Cequa™ is approved in the US and should be launched imminently. Sun Pharmaceuticals has the Worldwide rights, while Auven retains significant milestone and royalty interests extending through the patent life of Cequa.

Sun Press Release